Phenotypes Associated with This Genotype

Genotype
MGI:4887466

• Allelic Composition: Gt(ROSA)26Sor^{tm1.1(Otx2)Daac}/Gt(ROSA)26Sor^{tm1.1(Otx2)Daac}; Slc6a3^{tm1.1(cre)Bkmn}/Slc6a3⁺; Tg(CAG-Otx2,-GFP)21Asim/0
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6 * DBA/2

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

nervous system

decreased susceptibility to dopaminergic neuron neurotoxicity ( J:166896 )

• MPTP-treated mice exhibit increased number of tyrosine hydroxylase (TH)+ neurons in the substantia nigra pars compacta (SNpc) and ventral tegmental area (VTA) compared with Slc6a3^{tm1.1(cre)Bkmn} heterozygotes

decreased dopaminergic neuron number ( J:166896 )

• mice exhibit a reduction in the percentage of Kcnj6 (Girk2)+ or glyco-Slc6a3 (DAT)+ and tyrosine hydroxylase (TH)+ neurons in the ventral tegmental area (VTA) compared with wild-type mice

homeostasis/metabolism

decreased susceptibility to dopaminergic neuron neurotoxicity ( J:166896 )

• MPTP-treated mice exhibit increased number of tyrosine hydroxylase (TH)+ neurons in the substantia nigra pars compacta (SNpc) and ventral tegmental area (VTA) compared with Slc6a3^{tm1.1(cre)Bkmn} heterozygotes

cellular

decreased susceptibility to dopaminergic neuron neurotoxicity ( J:166896 )

• MPTP-treated mice exhibit increased number of tyrosine hydroxylase (TH)+ neurons in the substantia nigra pars compacta (SNpc) and ventral tegmental area (VTA) compared with Slc6a3^{tm1.1(cre)Bkmn} heterozygotes